INTRODUCTION
Infections caused by Gram-positive pathogens are frequently encountered in the healthcare setting and are associated with high morbidity and mortality [1] . Complicated skin and soft tissue infections (cSSTIs) caused by Staphylococcus aureus are among the most common bacterial infections, accounting for approximately 25% of all infections in clinical practice [1, 2] . Other Gram-positive bacterial infections include endocarditis, bacteremia, osteomyelitis, and foreign body or prosthetic device-related infections which are known to be difficult to treat.
Staphylococcus aureus is considered to be the most important cause of healthcare and community-associated infections worldwide [3, 4] . The European Union/European Economic Area population-weighted mean percentage of methicillin-resistant S. aureus (MRSA) infection was 18%, whereas 7 out of the 30 reporting countries had a prevalence of MRSA infections above 25% [5] . Among the available conventional therapies, vancomycin has been considered to be the main treatment option for MRSA infections [6] . Nonetheless, development of resistance and changes in MRSA susceptibility to vancomycin with increasing minimum inhibitory concentrations (MICs) have been observed [7] . Evidence supports the association between increased vancomycin MIC and worse patient outcome, with higher mortality in patients with bacteremia [8, 9] . In addition, slower clinical response and increased relapse rate have been associated with infections caused by MRSA with a high vancomycin MIC [10] .
Although vancomycin has been used as an alternative treatment for enterococci, the emergence of vancomycin-resistant enterococci (VRE) as leading cause of several nosocomial infections is a serious concern. Several other limitations of vancomycin use have been recognized such as poor tissue penetration, dosing in patients with renal failure and synergistic toxicity with concomitant aminoglycoside administration [6, 11] .
Resistance to currently available antibiotics is an alarming challenge in clinical settings [12] [13] [14] . As empirical treatment is often initiated where appropriate before identification of the infecting pathogen, first-line use of an antibiotic effective against resistant pathogens including MRSA is therefore preferable. The increased frequency of Gram-positive infections and the rise in resistance to commonly used antibiotics have led to the need for novel antibiotics [6, 14] .
Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against a wide range of [15] . It offers rapid recovery from infections, which reduces the risk of resistance development, and may shorten hospitalization and overall treatment costs [16, 17] . Further, as compared to vancomycin, daptomycin has a favorable renal safety profile with prolonged use [18, 19] .
The clinical experience with daptomycin since its approval in Europe, Latin America, and Asia has been captured by the European Cubicin Ò Outcomes Registry and Experience (EU-CORE SM ). EU-CORE, a retrospective, multicenter, and non-interventional study, was designed to collect real-world data of daptomycin treatment for Gram-positive infections. Interim results of EU-CORE were also published by Gonzalez-Ruiz and colleagues [20] . The objectives of this observational registry were to assess the clinical outcomes and safety of daptomycin in a large multicenter cohort of patients in clinical practice to reflect the real-world experience with daptomycin use.
METHODS

Patients and Data Collection
This analysis included data from patients across 18 countries in Europe (12), Latin America (5) The duration of treatment was evaluated as the number of inpatient and outpatient days during which the patient received daptomycin therapy, even if they were non-consecutive.
Clinical Outcomes
There were no restrictions on concomitant treatment. Data on prior and concomitant antibiotic therapy were collected.
Safety
Adverse events (AEs) and serious AEs (SAEs) reported during daptomycin treatment and after 30 days from the end of daptomycin therapy were recorded, regardless of the study drug relationship. Microbiologic data included the culture results obtained before or shortly after the initiation of daptomycin therapy.
Statistical Analysis
Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Due to the nature of the trial, inferential analyses were not conducted and no formal statistical methodology other than simple descriptive statistics was used. All analyses were considered to be explanatory.
Numerical variables were summarized as arithmetic mean, standard deviation, median, minimum, first quartile, third quartile, and maximum for continuous variables. Categorical variables were summarized by absolute and relative frequencies.
RESULTS
Patient Demographics and Clinical Characteristics
Overall, 6075 patients were included in the safety population; of these, 81 were pediatric patients. The patient demographic and clinical characteristics are described in Table 1 . The median age was 62.0 years. A total of 2777 (45.7%) patients were aged C65 years, including 1284 (21.1%) aged C75 years. Comorbidity was frequent as would be expected in seriously (Table 3) .
Staphylococcus epidermidis was the most common coagulase-negative staphylococcal (CoNS) pathogen (16.5%; Table 3 ).
Previous and Concomitant Antibiotic Therapies
Daptomycin was administered empirically in 3438 (56.6%) patients. A total of 3966 (65.3%) patients received antibiotics prior to daptomycin therapy. The most commonly 
Clinical Outcomes
The overall clinical success rate achieved with daptomycin treatment was 80.5%, and the rates were similar when daptomycin was used as firstline (82.9%) or second-line therapy (79.2%).
The clinical success rates across different infections were similar (Fig. 1) . Success rate by infection type independent of the treatment Fig. 1 Clinical outcome by primary infection. cSSTI complicated skin and soft tissue infection, uSSTI uncomplicated skin and soft tissue infection dose ranged between 73.9% for bacteremia and 89.3% for uSSTIs. Low failure rates were reported for various primary infections (Fig. 1 ). As shown in Fig. 2 , the clinical success rates by infecting pathogen were high for S. aureus. The clinical success rates showed an increasing trend with increasing daptomycin dose for endocarditis and foreign body/prosthetic infections (Fig. 3) . Higher clinical success rates were also observed with increased duration of daptomycin therapy (Fig. 4) reported SAEs, possibly related to daptomycin, by system organ class were investigations (n = 12, 0.2%), renal and urinary disorders (n = 11, 0.2%), and general disorders and administration site conditions (n = 6, 0.1%).
Infections and infestations (n = 78, 1.3%), concentrations were in the range of the ULN throughout the analysis period in most patients (Fig. 5) .
The total number of reported deaths during the study was 408 (6.7%). Five (0.1%) deaths were reported to be related to the study medication. The main causes of death were infections and infestations (3.4%), general disorders and administration site conditions (1.8%), multi-organ failure (1.4%), sepsis (1.3%), septic shock (1.2%), and cardiac disorders (1.1%).
DISCUSSION
The data from the EU-CORE registry illustrate Data from previous studies suggest that daptomycin is mostly used as second-line therapy; however, in approximately 10-40% of patients it is used as first-line therapy, based on type of infection [29] . In this study, daptomycin showed favorable effectiveness whether used as first-line (83.0%) or second-line (79.2%) therapy with or without concomitant antibiotics.
Daptomycin has an important role as first-line therapy for Gram-positive infections in terms of both effectiveness and cost considerations [21, 30] .
Additionally, the present study demonstrated similar effectiveness with daptomycin treatment against both MRSA and methicillin-susceptible S. aureus infections, thus supporting its use as an empirical therapy for
S. aureus infections. This observation is in line
with published guidelines that recommend daptomycin as the first alternative to vancomycin [31, 32] .
The recommended first-line therapies for treating MRSA infections are vancomycin and linezolid; however, these are associated with various safety concerns, particularly in longterm use. Nephrotoxicity and ototoxicity are the known major adverse reactions related to vancomycin use. The monitoring of trough concentrations to prevent nephrotoxicity is recommended (i.e., sustained troughs of 15-20 g/mL), especially in patients with unstable renal function or therapy for longer than 3-5 days [33, 34] . On the other hand, linezolid therapy has been reported to be associated with myelosuppression, peripheral and optic neuropathy, and lactic acidosis especially with prolonged use [35] . Further, linezolid-associated serotonergic and adrenergic drug interactions can lead to severe AEs such as hypertensive episodes [36] . [35, 37, 38] . Higher doses are also recommended for endocarditis and osteomyelitis by the Infectious Diseases
Society of America guidelines [31, 39] . Furthermore, toxicity may be a concern while increasing the dose of daptomycin and previous reports showed that high-dose daptomycin 
